drugset / Trial / NCT05926232

Expanded Access for Repotrectinib

NCT05926232

Expanded access Available Bristol-Myers Squibb

Summary

This is an expanded access designed to provide access to Repotrectinib for eligible participants.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Background Repotrectinib Small molecule

Indications

No indication recorded.